biostudies-literatureRosato RCompagnia di San Paolo (Fondazione Compagnia di San Paolo)Compagnia di San Paolo189-197https://www.ebi.ac.uk/biostudies/studies/S-EPMC12909112biostudies-literatureUnknown29(1)<h4>Background</h4>Real-world evidence on quality of life (QoL) changes associated with treatment decisions is crucial for informed choices by patients with low-risk prostate cancer (LRPC).<h4>Methods</h4>A prospective cohort study was conducted in the Piemonte and Valle d'Aosta Regional Oncology Network, NW Italy (4.5 million population), including nearly all urology (N = 22) and radiation oncology (N = 6) centres. Patients newly diagnosed with LRPC, eligible for radical treatments, received balanced information on risks and benefits of available options and could choose among active surveillance (AS), radical prostatectomy (RP), or radiotherapy (RT). Longitudinal changes in QoL were assessed via patient-reported outcomes in four domains: general QoL, mental health, sexual function and urProstate cancer and prostatic diseasesQuality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study.PMC129091122018.1377 ID ROL 29374 [Ciccone]De Luca SBillia MBeldi DGuercio SRossi RBollito ECante DSqueo MSMontefiore FDalmasso EDi Stasio AZarrelli GGalassi CBernardi DMuto GBiamino GPonti di Sant'Angelo FPorpiglia FSedigh OCastelli EPasquale MGuarneri AMigliari RPagano EStancati SFiorio MBellei LIorio CGMoroni MGontero PZaramella SMunoz FBardari FCollura DGirelli GVolpe ACentrella DVarvello FBorsa RBaima CGGatti MRosato RCiccone GBarale MCheccucci ERuggiero LGriffa DBellissimo AROderda MSTART Collaborative GroupZitella AGaribaldi ECoppola PSerao AfalseQuality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study.<h4>Background</h4>Real-world evidence on quality of life (QoL) changes associated with treatment decisions is crucial for informed choices by patients with low-risk prostate cancer (LRPC).<h4>Methods</h4>A prospective cohort study was conducted in the Piemonte and Valle d'Aosta Regional Oncology Network, NW Italy (4.5 million population), including nearly all urology (N = 22) and radiation oncology (N = 6) centres. Patients newly diagnosed with LRPC, eligible for radical treatments, received balanced information on risks and benefits of available options and could choose among active surveillance (AS), radical prostatectomy (RP), or radiotherapy (RT). Longitudinal changes in QoL were assessed via patient-reported outcomes in four domains: general QoL, mental health, sexual function and ur2026-01-01T00:00:00Z2026 Mar2026-07-16T00:48:55.457Z2026-07-09T13:09:47.747ZS-EPMC129091124109409310.1038/s41391-025-01032-0